gnckКолопроктологияKoloproktologia2073-75562686-7303Russian Association of Coloproctology10.33878/2073-7556-2023-22-3-94-103gnck-1827Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESОсобенности кишечной микробиоты у пациентов с колоректальным ракомCharacteristics of the intestinal microbiota in patients with colorectal cancerhttps://orcid.org/0000-0003-4795-0751СухинаМ. А.SukhinaM. A.

Сухина Марина Алексеевна — кандидат биологических наук, руководитель отдела микробиологических и иммунологических исследований; старший научный сотрудник лаборатории микробиологии и паразитологии

ул. Саляма Адиля, д. 2, г. Москва, 123423

ул. Погодинская, д. 10,с.1, г. Москва, 119121

Marina A. Sukhina — candidate of Sciences in Biology, Head of the Department of Microbiological and Immunological Research; Laboratory of Microbiology and Parasitology

Salyama Adilya st., 2, Moscow, 123423

Pogodinskaya st., 10-1, Moscow, 119121

sukchina-ma@yandex.ruhttps://orcid.org/0009-0005-0104-4843СтавцевМ. Г.StavtsevM. H.

Ставцев Матвей Гарриевич — младший научный сотрудник

ул. Саляма Адиля, д. 2, г. Москва, 123423

Matvey H. Stavtsev — junior researcher 

Salyama Adilya st., 2, Moscow, 123423

https://orcid.org/0000-0001-9294-5447АчкасовС. И.AchkasovS. I.

Ачкасов Сергей Иванович — член-корреспондент РАН, профессор, доктор медицинских наук, директор

ул. Саляма Адиля, д. 2, г. Москва, 123423

Sergey I. Achkasov — corresponding member RAS, professor, doctor of medical sciences, director 

Salyama Adilya st., 2, Moscow, 123423

https://orcid.org/0000-0002-7942-8004ЮдинС. М.YudinS. M.

Юдин Сергей Михайлович — доктор медицинских наук, профессор, Генеральный директор

ул. Погодинская, д. 10,с.1, г. Москва, 119121

Sergey M. Yudin — doctor of medical sciences, professor

Pogodinskaya st., 10-1, Moscow, 119121

ФГБУ "НМИЦ колопроктологии имени А.Н.Рыжих" Минздрава России; ФГБУ «ЦСП» ФМБА РоссииРоссияRyzhikh National Medical Research Center of Coloproctology; Federal State Budgetary Institution “Centre for Strategic Planning and Management of Biomedical Health Risks” of the Federal Medical Biological AgencyRussian FederationФГБУ "НМИЦ колопроктологии имени А.Н.Рыжих" Минздрава РоссииРоссияRyzhikh National Medical Research Center of ColoproctologyRussian FederationФГБУ «ЦСП» ФМБА РоссииРоссияFederal State Budgetary Institution “Centre for Strategic Planning and Management of Biomedical Health Risks” of the Federal Medical Biological AgencyRussian Federation20232109202322394103Copyright © Сухина М.А., Ставцев М.Г., Ачкасов С.И., Юдин С.М., 20232023Сухина М.А., Ставцев М.Г., Ачкасов С.И., Юдин С.М.Sukhina M.A., Stavtsev M.H., Achkasov S.I., Yudin S.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.ruproctology.com/jour/article/view/1827ЦЕЛЬ

ЦЕЛЬ: изучение кишечной микробиоты и выявление её характерных особенностей у пациентов с колоректальным раком.

ПАЦИЕНТЫ И МЕТОДЫ

ПАЦИЕНТЫ И МЕТОДЫ: в данном исследовании проанализирован состав кишечной микробиоты у пациентов с колоректальным раком, при этом группой сравнения явились пациенты с невоспалительными заболеваниями кишечника.

РЕЗУЛЬТАТЫ

РЕЗУЛЬТАТЫ: у пациентов с колоректальным раком отмечено увеличение доли энтерококков (12,7% - в исследуемой и 7,6% - в контрольной группах), снижение доли бифидобактерий (1,5% - в исследуемой группе и 4% - в контрольной группах) и облигатных анаэробов (3,3% - в исследуемой группе и 9,7% - в контрольной группе). Также было обнаружено снижение биоразнообразия микробиоты у пациентов с колоректальным раком, выраженное индексом Шеннона (4,46 у исследуемой группы и 4,8 в контрольной), и двукратное увеличение доли Pseudomonas aeruginosa (2,2% в исследуемой и 1,1% в контрольной группах), Clostridium septicum была изолирована только у пациентов с колоректальным раком.

ЗАКЛЮЧЕНИЕ

ЗАКЛЮЧЕНИЕ: результаты исследования позволяют предположить диагностическую значимость видового разнообразия кишечной микробиоты.

AIM

AIM: to study the intestinal microbiota and identify its characteristic features in patients with colorectal cancer.

PATIENTS AND METHODS

PATIENTS AND METHODS: in this study, the composition of the intestinal microbiota in patients with colorectal cancer was analyzed, while the comparison group consisted of patients with non-inflammatory bowel diseases.

RESULTS

RESULTS: previous studies have shown the possible role of enterococci and some types of clostridia in stimulating oncogenic processes and, on the contrary, the vital role of lactobacilli and bifidobacteria in intestinal homeostasis maintaining. The aim of this study was to compare the gut microbiota composition in colorectal cancer patients and non-inflammatory bowel diseases patients gut microbita. The proportion of enterococci was increased in patients with colorectal cancer (12.7% in the study group and 7.6% in the control group) on the contrary the proportion of bifidobacteria and obligate anaerobes was decreased (1.5% in the study group and 4% in the control groups) and (3.3 % of the study group and 9.7% in the control group) respectively. Decrease of the microbiota biodiversity was observed for the patients with colorectal cancer that was calculated by the Shannon diversity Index (4.46 in the study group and 4.8 in the control group), also two-fold increase of Pseudomonas aeruginosa share (2.2% in the study group and 1.1% in the control group) was found for this cohort, Clostridium septicum was isolated only from patients with colorectal cancer.

CONCLUSION

CONCLUSION: this study results suggest the diagnostic significance of the species diversity of the intestinal microbiota.

колоректальный ракмикробиотаанаэробыбутират-продуцирующие бактериипросветная микробиотапристеночная микробиотаcolorectal cancermicrobiotaanaerobesbutyrate-producing bacterialumen microbiotawall microbiotaГосзадание по АААА-А21-121012100067-7 «Изучение онкогенного потенциала микробиоты толстой кишки и определение ее роли в патогенезе колоректального рака»АААА-А21-121012100067-7 «Study of the oncogenic potential of the colon microbiota and determination of its role in the pathogenesis of colorectal cancer»Referencesde Martel C, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Heal International Agency for Research on Cancer. 2020; 8(2): e180–e190. DOI:10.1016/S2214-109X(19)30488-7de Martel C, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Heal International Agency for Research on Cancer. 2020; 8(2): e180–e190. DOI:10.1016/S2214-109X(19)30488-7Lawson JS, Glenn WK, Whitaker NJ. Breast Cancer as an Infectious Disease. Women’s Heal. 2010; 6(1): 5–8. DOI:10.2217/whe.09.73Lawson JS, Glenn WK, Whitaker NJ. Breast Cancer as an Infectious Disease. Women’s Heal. 2010; 6(1): 5–8. DOI:10.2217/whe.09.73Mason AL, Gilady SY, MacKey JR. Mouse mammary tumor virus in human breast cancer: Red herring or smoking gun? Am J Pathol Elsevier Inc. 2011; 179(4): 1588–1590. DOI:10.1016/j.ajpath.2011.08.003Mason AL, Gilady SY, MacKey JR. Mouse mammary tumor virus in human breast cancer: Red herring or smoking gun? Am J Pathol Elsevier Inc. 2011; 179(4): 1588–1590. DOI:10.1016/j.ajpath.2011.08.003Cheng Y, Ling Z, Li L. The Intestinal Microbiota and Colorectal Cancer. Front Immunol. 2020 November; 11: 1–13. DOI:10.3389/fimmu.2020.615056Cheng Y, Ling Z, Li L. The Intestinal Microbiota and Colorectal Cancer. Front Immunol. 2020 November; 11: 1–13. DOI:10.3389/fimmu.2020.615056Lotfollahzadeh S, Recio-Boiles A C.B.C.C. Colon Cancer. 2022. In: StatPearls [Internet]. Treasure Island (FL): S p. PMID:29262132.Lotfollahzadeh S, Recio-Boiles A C.B.C.C. Colon Cancer. 2022. In: StatPearls [Internet]. Treasure Island (FL): S p. PMID:29262132.Arnold M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017; 66(4): 683–691. DOI:10.1136/gutjnl-2015-310912Arnold M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017; 66(4): 683–691. DOI:10.1136/gutjnl-2015-310912Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. Nature Publishing Group, 2014;12(10): 661–672. DOI:10.1038/nrmicro3344Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. Nature Publishing Group, 2014;12(10): 661–672. DOI:10.1038/nrmicro3344Foulkes WD. Inherited Susceptibility to Common Cancers. N Engl J Med. Massachusetts Medical Society, 2008;359(20): 2143–2153. DOI:10.1056/NEJMra0802968Foulkes WD. Inherited Susceptibility to Common Cancers. N Engl J Med. Massachusetts Medical Society, 2008;359(20): 2143–2153. DOI:10.1056/NEJMra0802968Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007; 21(20): 2525–2538. DOI:10.1101/gad.1593107Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007; 21(20): 2525–2538. DOI:10.1101/gad.1593107Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database. Int J Cancer. 2002: 99(2): 260–266. DOI:10.1002/ijc.10332Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database. Int J Cancer. 2002: 99(2): 260–266. DOI:10.1002/ijc.10332Drewes JL, Housseau F, Sears CL. Sporadic colorectal cancer: Microbial contributors to disease prevention, development and therapy. Br J Cancer. Nature Publishing Group, 2016; 115(3): 273–280. DOI:10.1038/bjc.2016.189Drewes JL, Housseau F, Sears CL. Sporadic colorectal cancer: Microbial contributors to disease prevention, development and therapy. Br J Cancer. Nature Publishing Group, 2016; 115(3): 273–280. DOI:10.1038/bjc.2016.189Tlaskalova-Hogenova H, et al. Microbiome and colorectal carcinoma: Insights from germ-free and conventional animal models. Cancer J. (United States). 2014; 20(3): 217–224. DOI:10.1097/ppo.0000000000000052Tlaskalova-Hogenova H, et al. Microbiome and colorectal carcinoma: Insights from germ-free and conventional animal models. Cancer J. (United States). 2014; 20(3): 217–224. DOI:10.1097/ppo.0000000000000052Zhu Q, et al. Analysis of the intestinal lumen microbiota in an animal model of colorectal cancer. PLoS One. 2014; 9(3): 1–10. DOI:10.1371/journal.pone.0090849Zhu Q, et al. Analysis of the intestinal lumen microbiota in an animal model of colorectal cancer. PLoS One. 2014; 9(3): 1–10. DOI:10.1371/journal.pone.0090849Kajihara T, et al. Clinical characteristics and risk factors of enterococcal infections in Nagasaki, Japan: A retrospective study. BMC Infect. Dis. BMC Infectious Diseases. 2015;15(1):1175-6. DOI:10.1186/s12879-015-1175-6Kajihara T, et al. Clinical characteristics and risk factors of enterococcal infections in Nagasaki, Japan: A retrospective study. BMC Infect. Dis. BMC Infectious Diseases. 2015;15(1):1175-6. DOI:10.1186/s12879-015-1175-6Amarnani R, Rapose A. Colon cancer and enterococcus bacteremia co-affection: A dangerous alliance. J Infect Public Health. King Saud Bin Abdulaziz University for Health Sciences, 2017; 10(5): 681–684. DOI:10.1016/j.jiph.2016.09.009Amarnani R, Rapose A. Colon cancer and enterococcus bacteremia co-affection: A dangerous alliance. J Infect Public Health. King Saud Bin Abdulaziz University for Health Sciences, 2017; 10(5): 681–684. DOI:10.1016/j.jiph.2016.09.009Li S, et al. Tumorigenic bacteria in colorectal cancer: mechanisms and treatments. Cancer Biol Med. 2022. Vol. 19, № 2. P. 147–162. doi:10.20892/j.issn.2095-3941.2020.0651Li S, et al. Tumorigenic bacteria in colorectal cancer: mechanisms and treatments. Cancer Biol Med. 2022. Vol. 19, № 2. P. 147–162. doi:10.20892/j.issn.2095-3941.2020.0651Ruiz PA, et al. Fail to Inhibit Proinflammatory Gene Expression in Intestinal. 2016. DOI:10.4049/jimmunol.174.5.2Ruiz PA, et al. Fail to Inhibit Proinflammatory Gene Expression in Intestinal. 2016. DOI:10.4049/jimmunol.174.5.2Wang X, Huycke MM. Extracellular Superoxide Production by Enterococcus faecalis Promotes Chromosomal Instability in Mammalian Cells. Gastroenterology. 2007; 132(2): 551–561. DOI:10.1053/j. Gastro.2006.11.040Wang X, Huycke MM. Extracellular Superoxide Production by Enterococcus faecalis Promotes Chromosomal Instability in Mammalian Cells. Gastroenterology. 2007; 132(2): 551–561. DOI:10.1053/j. Gastro.2006.11.040Mirza NN, McCloud JM, Cheetham MJ. Clostridium septicum sepsis and colorectal cancer - A reminder. World J Surg Oncol. 2009; 7: 73. DOI: 10.1186/1477-7819-7-73Mirza NN, McCloud JM, Cheetham MJ. Clostridium septicum sepsis and colorectal cancer - A reminder. World J Surg Oncol. 2009; 7: 73. DOI: 10.1186/1477-7819-7-73Kuperman AA, et al. Deep microbial analysis of multiple placentas shows no evidence for a placental microbiome. BJOG An Int J Obstet Gynaecol. 2020; 127(2): 159–169. DOI:10.1111/1471-0528.15896.Kuperman AA, et al. Deep microbial analysis of multiple placentas shows no evidence for a placental microbiome. BJOG An Int J Obstet Gynaecol. 2020; 127(2): 159–169. DOI:10.1111/1471-0528.15896.Milani C, et al. The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota. Microbiol Mol Biol Rev. 2017; 81(4):1–67. DOI:10.1128/MMBR.00036-17Milani C, et al. The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota. Microbiol Mol Biol Rev. 2017; 81(4):1–67. DOI:10.1128/MMBR.00036-17Collado MC, et al. Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid. Sci Rep Nature Publishing Group. 2016; 6(October 2015): 1–13. DOI:10.1038/srep23129Collado MC, et al. Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid. Sci Rep Nature Publishing Group. 2016; 6(October 2015): 1–13. DOI:10.1038/srep23129Alessandri G, et al. Bifidobacterial Dialogue With Its Human Host and Consequent Modulation of the Immune System. Front Immunol. 2019;10(October). DOI:10.3389/fimmu.2019.02348Alessandri G, et al. Bifidobacterial Dialogue With Its Human Host and Consequent Modulation of the Immune System. Front Immunol. 2019;10(October). DOI:10.3389/fimmu.2019.02348Bunesova V, Lacroix C, Schwab C. Mucin Cross-Feeding of Infant Bifidobacteria and Eubacterium hallii. Microb Ecol Microbial Ecology. 2018; 75(1): 228–238. DOI:0.1007/s00248-017-1037-4Bunesova V, Lacroix C, Schwab C. Mucin Cross-Feeding of Infant Bifidobacteria and Eubacterium hallii. Microb Ecol Microbial Ecology. 2018; 75(1): 228–238. DOI:0.1007/s00248-017-1037-4Den Besten G, et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013; 54(9): 2325–2340. DOI:10.1194/jlr.R03601Den Besten G, et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013; 54(9): 2325–2340. DOI:10.1194/jlr.R03601Ríos-Covián D, et al. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol. 2016; 7( FEB):1–9. DOI:10.3389/fmicb.2016.00185Ríos-Covián D, et al. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol. 2016; 7( FEB):1–9. DOI:10.3389/fmicb.2016.00185Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016; 7(3): 189–200. DOI:10.1080/19490976.2015.1134082Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016; 7(3): 189–200. DOI:10.1080/19490976.2015.1134082Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: Major fermentation by-products and their impact on host health. Microbiome. 2019; 7(1): 1–15. DOI:0.1186/s40168-019-0704-8Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: Major fermentation by-products and their impact on host health. Microbiome. 2019; 7(1): 1–15. DOI:0.1186/s40168-019-0704-8

The authors declare that there are no conflicts of interest present.